戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 edefining, rebranding and co-opting what is 'biopharmaceutical'.
2 tructural biology and the development of new biopharmaceuticals.
3 uitable for the high-throughput screening of biopharmaceuticals.
4 in the clinical development of plant-derived biopharmaceuticals.
5  be exploited further in the design of novel biopharmaceuticals.
6 y be used for quality control of recombinant biopharmaceuticals.
7 es are currently the most important class of biopharmaceuticals.
8 n proteins, are a novel and growing class of biopharmaceuticals.
9 is critically important to the production of biopharmaceuticals.
10 ges, limiting their effective application as biopharmaceuticals.
11 t monoclonal IgG1 antibody, a major class of biopharmaceuticals.
12 detected modifications of well-characterized biopharmaceuticals.
13 monitoring conformational changes in protein biopharmaceuticals.
14 onoclonal antibodies are a major subclass of biopharmaceuticals.
15 stems for production of vaccine antigens and biopharmaceuticals.
16 ation has turned proteins into important new biopharmaceuticals.
17 cturing platform for the production of human biopharmaceuticals.
18 at engineered antibodies have come of age as biopharmaceuticals.
19  express high levels of vaccine antigens and biopharmaceuticals.
20 ocedure in view of the production of SLM for biopharmaceutical and biotech protocols.
21                                              Biopharmaceutical and biotechnology companies and regula
22 rotein acidostability is a common problem in biopharmaceutical and other industries.
23  (ELISA) is a widely used tool for analyzing biopharmaceutical and vaccine products.
24                                         Such biopharmaceuticals and edible vaccines can be stored and
25 pportunities for the optimization of protein biopharmaceuticals and for the development of cell-perme
26 mon chemical degradation pathway observed in biopharmaceuticals and is particularly prevalent in synt
27  a catalyst for the development of vaccines, biopharmaceuticals and small molecule therapeutics.
28 are important to both the supply of marketed biopharmaceuticals and the pipelines of novel therapeuti
29  sialylated O-glycans most commonly found on biopharmaceuticals) and bovine submaxillary gland mucin
30 cterization and quality control step for any biopharmaceutical, and this is usually measured by fluor
31 ationship in the context of physicochemical, biopharmaceutical, and toxicological profiling.
32 ential, utility in large-scale production of biopharmaceuticals, and the capacity to act as probes to
33 vel has a great potential for biomedical and biopharmaceutical applications.
34 -specific reactive immunization, a potential biopharmaceutical approach to glycation-related patholog
35                           Here, the data for biopharmaceuticals approved between 1995 and 1999 are pr
36 e clinical and approval phases of the 26 new biopharmaceuticals approved by the US Food and Drug Admi
37                                      Protein biopharmaceuticals are an important and growing area of
38                                Protein-based biopharmaceuticals are becoming increasingly widely used
39    Monoclonal antibodies and recombinant DNA biopharmaceuticals are derived from relatively homogeneo
40                                      As many biopharmaceuticals are glycosylated in order to be funct
41                              As more protein biopharmaceuticals are produced using mammalian cell cul
42 nal antibodies, the fastest growing class of biopharmaceuticals, as well as membrane-associated and c
43 horesis and cIEF should be considered during biopharmaceutical assay development.
44 Antibody fragments are emerging as promising biopharmaceuticals because of their relatively small siz
45         A key challenge for the academic and biopharmaceutical communities is the rapid and scalable
46                    A majority of the largest biopharmaceutical companies have announced strategic par
47  in which it established collaborations with biopharmaceutical companies to support early-stage effor
48    The desire to deliver protein and peptide biopharmaceuticals conveniently and effectively has led
49  clinical trials are proceeding on the first biopharmaceuticals derived from them.
50 a convenient quality examination tool during biopharmaceutical development and manufacturing processe
51                        A major limitation in biopharmaceutical development is selectively targeting d
52  therefore offers significant advantages for biopharmaceutical development laboratories.
53 trifugation (SV-AUC) is routinely applied in biopharmaceutical development to measure levels of prote
54         In protein chemistry, proteomics and biopharmaceutical development, there is a desire to know
55  represent the dominant production hosts for biopharmaceutical development, yet the physiology of the
56 apeutic) proteins, which are widely used for biopharmaceutical development.
57 ant targets for fundamental research and for biopharmaceutical development.
58 nt for biomolecular research, diagnosis, and biopharmaceutical development.
59 ologies that are increasingly being used for biopharmaceutical drug discovery.
60                             In recent years, biopharmaceutical drug products have become hugely succe
61 m may be in the high-throughput screening of biopharmaceutical drugs that are potential inhibitors of
62 ng remains a challenge in the formulation of biopharmaceuticals due to artifacts associated with each
63 n studies of skin-impermeant medications and biopharmaceuticals for clinical applications.
64         The rapid maturation of the field of biopharmaceutical formulation is the result of the simul
65 ths that take place during the production of biopharmaceuticals from animal cell lines.
66                 One transgenic plant-derived biopharmaceutical, hirudin, is now being commercially pr
67 thalmology is likely to involve the areas of biopharmaceuticals, implantable materials (e.g. tissue r
68 yield bioreactor for the production of human biopharmaceuticals in egg whites using genetic engineeri
69 yield bioreactor for the production of human biopharmaceuticals in egg whites.
70 d clinical development of safe and effective biopharmaceuticals in plant hosts.
71   They are structurally different from other biopharmaceuticals in size and quaternary structure.
72 gs, the conformational properties of protein biopharmaceuticals in solution are influenced by a varie
73 heterologous proteins of high quality in the biopharmaceutical, industrial and academic environments.
74 apeutic glycoproteins has been emphasized in biopharmaceutical industries because the carbohydrate co
75 racentrifugation (SV-AUC) has emerged in the biopharmaceutical industry as a technique to detect smal
76 mass spectrometry can and should play in the biopharmaceutical industry beyond the presently assigned
77 rch efforts in academic institutions and the biopharmaceutical industry have become increasingly tran
78 f therapeutic and endogenous proteins in the biopharmaceutical industry over the past several years,
79 s, it becomes increasingly important for the biopharmaceutical industry to have tools to characterize
80  biosyntheses, once only in the realm of the biopharmaceutical industry, have now been embraced by th
81                                   Within the biopharmaceutical industry, recombinant plasmid DNA is u
82                              For the protein biopharmaceutical industry, therefore, it is important t
83   Biologic drugs are promoting growth in the biopharmaceutical industry.
84 tic antibodies is of great importance to the biopharmaceutical industry.
85 enteral administration are of concern in the biopharmaceutical industry.
86 ations (PTMs) of recombinant proteins in the biopharmaceutical industry.
87 proteins is of increasing interesting in the biopharmaceutical industry.
88 es have become a major driving force for the biopharmaceutical industry; therefore, the discovery and
89                   The manufacture of protein biopharmaceuticals is conducted under current good manuf
90 on of an expression platform for recombinant biopharmaceuticals is often centered upon suitable produ
91 odies is an area of significant focus in the biopharmaceutical landscape.
92 cal assets in the discovery and selection of biopharmaceutical lead candidates.
93 an orally, both of which suggest substantial biopharmaceutical liabilities.
94                                              Biopharmaceutical manufacturing capacity has moved throu
95                   Some of the most expensive biopharmaceuticals of restricted availability, such as g
96 ajor costs associated with the production of biopharmaceuticals or vaccines in fermentation-based sys
97 mi-synthetic availability, purity and cost), biopharmaceutical (poor bioavailability and limiting pha
98 ic agents, and the characterization of these biopharmaceuticals poses a significant analytical challe
99                                           In biopharmaceutical process development, it is desirable t
100   The potential impact of transcriptomics on biopharmaceutical process technology is also discussed.
101  detection and monitoring of this epitope in biopharmaceuticals produced in recombinant mammalian sys
102                 In some cases, delivery of a biopharmaceutical product by direct ingestion of the mod
103 ing protein aggregation at various stages of biopharmaceutical product design.
104 characterizing conformational changes in the biopharmaceutical product interferon beta-1a (IFN-beta-1
105 omposite mixtures of antibodies representing biopharmaceutical products coexpressed from single cells
106 e tool for characterization of heterogeneous biopharmaceutical products such as bispecific antibodies
107 with molecular biology to yield more than 40 biopharmaceutical products, such as erythropoietin, huma
108 sed attention to quality by design (QbD) for biopharmaceutical products, there is a demand for accura
109 ualitative and semiquantitative profiling of biopharmaceutical products.
110 iseases to development of safe and efficient biopharmaceutical products.
111                                 The modified biopharmaceutical properties of 3 translated into excell
112             Chemical modification to improve biopharmaceutical properties, especially oral absorption
113 potency and unattractive pharmacological and biopharmaceutical properties.
114 g selectivity for JAK3 versus JAK1, and good biopharmaceutical properties.
115 considerable potential for the production of biopharmaceutical proteins and peptides because they are
116                             Oral delivery of biopharmaceutical proteins expressed in plant cells shou
117 e quality and quantity of pharmaceutical and biopharmaceutical research has changed.
118 easing attention in biological, medical, and biopharmaceutical research.
119 ble oral bioavailability of CsA represents a biopharmaceutical risk factor for the occurrence of chro
120 mer's) but also due to its importance in the biopharmaceutical sector, where aggregation of protein t
121 ave application across both the chemical and biopharmaceutical sectors.
122 g pathways is essential to the production of biopharmaceuticals since commercial production of recomb
123 timately resulted in the current experienced biopharmaceutical stronghold in the therapeutic market.
124 an be used for the production of recombinant biopharmaceuticals such as cytokines, hormones, monoclon
125 demonstrate the utility of the HBD of NRG in biopharmaceutical targeting and provide a new way to blo
126                                              Biopharmaceuticals that target specific disease-mediatin
127                                 When used as biopharmaceutical therapeutics, such heterogeneities may
128 recent advances in yeast-based expression of biopharmaceuticals will be discussed.
129 ing, purifying, and formulating a commercial biopharmaceutical with consistent therapeutic properties
130 dily supports large-scale glycan analysis of biopharmaceuticals with rapid deglycosylation times.
131 in biosensors), or as nonimmunogenic in vivo biopharmaceuticals with superior biodistribution and blo

WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。
 
Page Top